Compare SOPH & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOPH | BRBI |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | Switzerland | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 402.4M |
| IPO Year | 2021 | 2025 |
| Metric | SOPH | BRBI |
|---|---|---|
| Price | $7.07 | $7.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 524.7K | 5.7K |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | N/A | ★ 14.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.25 | N/A |
| Revenue Next Year | $24.62 | $13.87 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $6.87 |
| 52 Week High | $8.98 | $16.61 |
| Indicator | SOPH | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 30.27 |
| Support Level | $4.58 | N/A |
| Resistance Level | $8.80 | $14.86 |
| Average True Range (ATR) | 0.47 | 0.66 |
| MACD | 0.06 | -0.86 |
| Stochastic Oscillator | 44.75 | 4.96 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.